Browsing "Endocrinology & Metabolism" by Keyword : Metformin
Showing results 13 to 22 of 22
| Pub Year | | Title | Author(s) |
| 2018 | | Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program | 김대중, 김혜진, 이관우, 전자영, 한승진 |
| 2011 | | Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. | 김혜진 |
| 2019 | | Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study | 이관우 |
| 2017 | | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies | 김대중, 이광재 |
| 2015 | | Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. | 이관우 |
| 2018 | | Long-term effects on glycaemic control and beta-cell preservation of early intensive treatment in patients with newly diagnosed type 2 diabetes: A multicentre randomized trial | 이관우 |
| 2018 | | Metformin reduces the risk of cancer in patients with type 2 diabetes: An analysis based on the Korean National Diabetes Program Cohort | 김대중, 김혜진, 이관우, 전기홍, 전자영, 한승진 |
| 2019 | | Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study | 김대중, 하경화 |
| 2007 | | The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. | 김대중 |
| 2014 | | The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study. | 김대중, 김혜진, 이관우, 한승진 |
1
